Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer

29 May 2017

Abstract excerpt

// Montserrat Pérez-Salvia 1 , Laia Simó-Riudalbas 1 , Pere Llinàs-Arias 1 , Laura Roa 1 , Fernando Setien 1 , Marta Soler 1 , Manuel Castro de Moura 1 , James E. Bradner 2 , Eva Gonzalez-Suarez 1 , Catia Moutinho 1 and Manel Esteller 1, 3, 4 1 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain 2 Novartis Institutes for Biomedical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28881673
DOI: 10.18632/oncotarget.18255

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancerPMID 28881673Read ↗

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsSemantic proximity Read ↗

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycSemantic proximity Read ↗

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell LymphomaSemantic proximity Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseasesSemantic proximity Read ↗

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1Semantic proximity Read ↗

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.